AVEO Pharmaceuticals — Investor Presentation (April 2016)
39 slides from AVEO Pharmaceuticals's investor presentation, Apr 4, 2016
Slide 1: AVEO Overview April 2016
AVEO Overview April 2016 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are
Slide 3: AVEO Oncology Highlights
AVEO Oncology Highlights Significant N.A. rights for all oncology therapeutic assets Retained North American tivozanib oncology rights TIVO-3 pivotal refractory RCC study planned to support both 1st & 3rd line indications in U.S. Exploring immunotherapy combination in RCC and CRC biomarker Ficlatuzu
Slide 4: Retaining North American Rights in Oncology While Leveraging Partnerships
Retaining North American Rights in Oncology While Leveraging Partnerships to Advance Our Pipeline AV-380 GDF15 MAb Tivozanib VEGF 123 TKI (Oncology Indications) AV-203 ERBB3 MAb Ficlatuzumab HGF MAb Value Creation Strategy Leverage partner resources to advance development, retain significant downstr
Slide 5: Partnerships Provide Significant Downstream Value Potential
Partnerships Provide Significant Downstream Value Potential, Support for North American Strategy Tivozanib EU, Other December 2015 Tivozanib Ocular November 2014 Tivozanib Russia, Ukraine, CIS August 2015 AV-380 August 2015 Ficlatuzumab April 2014 Potential for ~$1 Billion in partnership payments pl
Slide 6: Multiple Opportunities for Value Creation
TIVO-1 (1st Line RCC) * Ocular FOCAL (Phase 2 Study in NSCLC) NRG-1 Biomarker Solid Tumors Cachexia TIVO-3 (U.S. Phase 3 Registration Study in RCC) NRP-1 CRC PD-1 RCC Multiple Opportunities for Value Creation * Filed in Russia by Pharmstandard DEC 28, 2015 Filed in EU by EUSA FEB 29, 2016, validated
Slide 7: Tivozanib
Tivozanib A potent, selective, long half-life inhibitor of vascular endothelial growth factor (VEGF) 1, 2 and 3 receptors
Slide 8: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:
Slide 9: The RCC Opportunity
The RCC Opportunity ~$1.5 Billion ~$1.0 Billion Large market opportunity: ~$2.5 billion in Europe and North America* Future market needs: Improved tolerability Increased efficacy through combinations with immunotherapy * Total RCC market includes all stages of disease and treatment options. Source:
Slide 10: Tivozanib Properties May Provide for Optimal Combination with PD-1 Inhibitors
Tivozanib Properties May Provide for Optimal Combination with PD-1 Inhibitors Where other VEGFR TKIs have had challenges combining with other agents, tivozanib has been demonstrated to safely combine at full dose in several studies: mRCC: Tivozanib + Temsirolimus (Torisel) mBC: Tivozanib + Paclitaxe
Slide 11: Tivozanib RCC Front-line Setting
Tivozanib RCC Front-line Setting
Slide 12: TIVO-1: Proven Activity in 1st line RCC
Phase 3 TIVO-1: Proven Activity in 1st line RCC 517 patient, global, randomized Phase 3 in 1st line RCC First H2H RCC pivotal to meet primary PFS endpoint of superiority vs VEGF TKI OS confounded by crossover; NDA not approved; FDA requested additional study Demonstrated favorable tolerability profi
Slide 13: Comparable OS Despite Limited Subsequent Therapy
Comparable OS Despite Limited Subsequent Therapy
Slide 14: Support for Tivozanib MAA Filing for RCC
Support for Tivozanib MAA Filing for RCC TIVO-1: Impact of Next-Line Therapy on OS * EU includes Bulgaria, Czech Republic, France, UK, Hungary, Italy, Poland, Romania (countries with patients enrolled in Study 301) ** EU5 includes UK, Italy, and France (EU5 countries with patients enrolled in Study
Slide 15: Tivozanib: Regional Oncology Licensing Agreements
Tivozanib: Regional Oncology Licensing Agreements EU filing 2/29/16 >$396M in Upfront and Potential Milestones $16M potential 2016/17 milestones* Tiered royalties from low double digits to mid twenties Russian Filing 12/28/15 $12M in Upfront and Potential Milestones^ $7.5M upon approval** ^ High sin
Slide 16: Favorable Tolerability vs. Approved TKIs in RCC
Favorable Tolerability vs. Approved TKIs in RCC 1. AVEO Data on file; 2. INLYTA prescribing information v.01.2012; 3.Votrient prescribing information revised 01.2012; 4. Sutent prescribing information revised 05.2011; 5. Cabozantinib METEOR Trial NEJM 9.2015 Cabozantinib: 60% Dose Reductions5 Incide
Slide 17: Tivozanib is Well Tolerated, Potential Preferred TKI for Combination
Tivozanib is Well Tolerated, and Has the Potential to Become the Preferred TKI for Combination Therapy Single Agent Toxicity All grade (Gr 3/4) Sutent1 (n=548) Votrient1 (n=554) Inlyta3 (n=359) Nexavar4 (n=257) Cometriq2 (n=331) Tivozanib4 (n=259) Hypertension 30% (15%) 40% (4%) 40% (16%) 34% (17%)
Slide 18: Top Three Toxicities Relevant to Patients with Advanced RCC
Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events >50% of pts on Nexavar <15% for Tivozanib >60% of pts on Sutent <20% for Tivozanib >50% of pts on Pazopanib, Axitinib and
Slide 19: Tivozanib North American Registration Strategy
Tivozanib North American Registration Strategy
Slide 20: TIVO-3: Planned Phase 3 Study Design in Recurrent/Metastatic RCC
TIVO-3: Planned Phase 3 Study Design in Recurrent/Metastatic RCC to Confirm TIVO-1 N = ~322 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and tolerability for ITT & P
Slide 21: Tivozanib Efficacy in VEGF TKI Refractory Setting
Tivozanib Efficacy in VEGF TKI Refractory Setting * n= 389; investigator assessed PFS; independent PFS = 4.8 mo vs. 3.4 mo, HR = 0.741 (p=0.011) **investigator assessed PFS Motzer et al Lancet Oncol 2013; 14: 552–62 Motzer et al Lancet Oncol 2014 Hutson et al ASCO 2015 Motzer ESMO 2015 Motzer ESMO 2
Slide 22: Potential Path to Value Creation: U.S. Registration Strategy in RCC
Potential Path to Value Creation U.S. Registration Strategy in RCC ASCO 2015 Updated VEGF TKI refractory PFS data from TIVO-1 crossover FDA Feedback P3 refractory study for 3rd line and potential confirmatory study for 1st line Phase 3 Registration Study in RCC (TIVO-3) Estimated 2Q 2016 Start Poten
Slide 23: Tivozanib PD-1 Combination Setting
Tivozanib PD-1 Combination Setting
Slide 24: Rationale for combining VEGF + PD-(L)1 inhibitors
Rationale for combining VEGF + PD-(L)1 inhibitors Gunturi, McDermoot Current Treatment Options in Oncology 2014 Pilmack International Kidney Cancer Symposium 2014
Slide 25: Tivozanib Properties Favorable for PD-1 Combination
Tivozanib Properties Favorable for PD-1 Combination Pawlowski N et al. AACR 2013. Poster 3971.
Slide 26: Early Data for Axitinib + Pembrolizumab: Promising Efficacy, Challenging Toxicity
Early Data for the Combination of Axitinib + Pembrolizumab: Demonstrated Promising Efficacy, Challenging Toxicity Atkins et al, SITC 2015 Three DLTs reported: transient ischemic attack (TIA; n=1) and < 75% of planned axitinib dose received due to treatment-related toxicity (n=2, diarrhea and arthral
Slide 27: Toxicity in Select TKI Combinations with PD-1s
Toxicity in Select TKI Combinations with PD-1s Courtesy of Dr. S. Pal, ASCO GU 2015
Slide 28: Comparison of Liver AEs in TKIs
Axitinib Tivozanib Axitinib Tivozanib Comparison of Liver AEs in TKIs Liver AEs are significantly higher for sutent, pazopanib and axitinib, compared to tivozanib When TKIs and PD1s are combined, the increase in Grade 3/4 AEs is more than additive When combined with PD1, Grade 1/2 AEs appear to be a
Slide 29: Tivozanib Other Indications
Tivozanib Other Indications
Slide 30: Tivozanib: Non-Oncology Exclusive License Agreement
Tivozanib: Non-Oncology Exclusive License Agreement >$105M total in upfront and potential option & milestone payments Potential for $10M in 2016 Tiered, double digit royalties, up to the mid-teens, on net sales* Figures from Ophthotech R&D Investor Day Dec 3, 2015 Option, milestone and royalty payme
Slide 31: Low NRP-1 Biomarker Predictive for Tivozanib Benefit over Bevacizumab
Low NRP-1 Biomarker (50% of Pts) was Predictive for Tivozanib Benefit over Bevacizumab* aUnstratified analysis: (n=80; events=31); log rank test P value=0.0075; HR (95% CI): 0.38 (0.183, 0.794). *Utilizing predefined median NRP-1 cutoff
Slide 32: Robust Pipeline Development Funded by Partnerships
Robust Pipeline Development Funded by Partnerships
Slide 33: Advancing Robust Pipeline Through Partnership
Advancing Robust Pipeline Through Partnership Milestone and royalty payments subject to the successful development and/or commercialization of the product *A percentage of proceeds will be shared with SVH, including of $1.5 million of upfront AV-380 (GDF-15 inhibitor MAb) Indication: Cachexia Incide
Slide 34: Financials & Summary
Financials & Summary
Slide 35: Financial Highlights
Financial Highlights $34.1M in cash and investments as of year end 2015 Excludes $3.5M received from Novartis, $4M paid for SEC settlement and $1M CANbridge upfront payment Sufficient to fund operations at least into the fourth quarter of 2017* >$40M in potential payments through mid-2017 including:
Slide 36: Significant Progress During 2015 and early 2016
Significant Progress During 2015 and early 2016 Tivozanib FDA feedback on RCC registration plan Rapporteur feedback for European filing Filing in Russia and EU, acceptance of both files Partnership in EU Partnership in Russia ASCO presentation of refractory RCC data Presentation of encouraging CRC d
Slide 37: Potential Corporate Milestones
Potential Corporate Milestones Tivozanib Initiation of 3rd line confirmatory RCC Phase 3 study (2Q16) Initiation of Phase 1 PD-1 combination study Initiation of Phase 2/Phase 3 CRC study (with CDx identification) Regulatory decision in Russia/Ukraine/CIS Regulatory decision in EU Proof of concept in
Slide 38: AVEO Oncology Highlights
AVEO Oncology Highlights Significant N.A. rights for all oncology therapeutic assets Retained North American tivozanib oncology rights TIVO-3 pivotal refractory RCC study planned to support both 1st & 3rd line indications in U.S. Exploring immunotherapy combination in RCC and CRC biomarker Ficlatuzu
Slide 39: AVEO Overview April 2016
AVEO Overview April 2016
AVEO Pharmaceuticals — Investor Presentation (April 2016) on 6ix